CYTK vs NVS
Cytokinetics Inc (CYTK) versus NVS (NVS) — a side-by-side from cached financials, not a winner call.
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
NVS (NVS) common stock.
Latest reported CYTK revenue for 2026-06-30 was $28.6M. Net income was -$198.8M. Revenue was up 47.9% from 2026-03-31 to 2026-06-30. CYTK currently screens at market cap $4.05B.
NVS does not have a complete income-statement cache yet.
CYTK currently screens at market cap $4.05B. NVS currently screens at market cap $0.
Not investment advice. Open the CYTK and NVS stock pages for the full models.
Not investment advice.